$ACST It is not an easy PR. This is what I understood from my complete ignorance: The point is that many patients already reduced their TG levels considerably even before started taking the pills (some of them CaPre and some of them just placebo, randomly). Why? They do not say anything about that. Then they just take the TG levels in day 0 as the baseline and they make a smaller population (taking into consideration that at day 0 they need to have the TG levels between >500 mg/dL and <1500mg/dL as specified in the trial protocol, thus patients that on day 0 were out of these levels were removed). Then they analyze the results of these new population taking day 0 levels as baseline. The new results obtained this way are much better, where the CaPre patients have much more reduction than the placebo group. What worries me is the last sentence in the "conclusions". Don't get me wrong, I am holding a big bag so I hope it is overall good news, but this sentence worries me...